-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Caribou Biosciences announced that its CRISPR-based gene editing-engineered ready-to-use CAR-T therapy CB-010 has achieved positive results in a Phase 1 clinical trial in patients with relapsed/refractory B-cell non-Hodgkin lympho.
100% overall response rate and 80% complete response rate among 5 patients receiving initial dose of CRISPR gene-edited ready-to-use CAR-T therapy CB-010 CB-010 is the first to achieve 100% overall response rate Allogeneic CAR-T therapy is also the first clinical-stage allogeneic CAR-T therapy with PD-1 knocko.
In addition to expressing a chimeric antigen receptor (CAR) targeting CD19, gene editing was used to knock down the expression of the immune checkpoint protein PD-1, aiming to improve the persistence of antitumor activi.
▲Introduction of CB-010 (Image source: Caribou Biosciences official website)
▲Introduction of CB-010 (Image source: Caribou Biosciences official website)As of February 23, 2022, 6 patients had received CB-010, and 5 patients had completed the dose-limiting toxicity assessment at 28 da.
All 4 patients who achieved complete remission at 28 days had continued remission at 3 mont.
▲ Results of patients treated with CB-010 (Image source: Caribou Biosciences official website)
▲ Results of patients treated with CB-010 (Image source: Caribou Biosciences official website)In terms of safety, no graft-versus-host disease was found, and one patient developed grade 1 cytokine release syndrome (CRS) and grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS), which were defined as dose-limiting toxiciti.
Based on the positive safety and efficacy data obtained in this cohort of patients, this clinical trial will enroll patients to receive higher doses of CB-01
"Our initial data for CB-010 are exciti.
References:
References:[1] Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Thera.
[1] Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Thera.
[2] CB-010 Clinical Program Upda.
Retrieved May 12, 2022, from https://invest.
cariboub.
com/static-files/cd6999e4-39cc-4157-881e-06cab012fa85
